Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Apellis Pharmaceuticals Q3 EPS $1.67 Beats $0.92 Estimate, Sales $458.578M Beat $406.678M Estimate

Author: Benzinga Newsdesk | October 30, 2025 06:06am
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate of $0.92 by 80.93 percent. This is a 463.04 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $458.578 million which beat the analyst consensus estimate of $406.678 million by 12.76 percent. This is a 132.98 percent increase over sales of $196.830 million the same period last year.

Posted In: APLS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist